Short Interest in Innate Pharma S.A. (NASDAQ:IPHA) Drops By 82.5%

Innate Pharma S.A. (NASDAQ:IPHA - Get Free Report) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 65,700 shares, a decline of 82.5% from the April 30th total of 376,100 shares. Based on an average trading volume of 35,300 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.1% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $11.00 target price (down from $11.50) on shares of Innate Pharma in a report on Thursday, April 24th.

Innate Pharma Stock Down 2.2%

NASDAQ:IPHA traded down $0.05 during trading hours on Monday, hitting $2.14. 3,163 shares of the stock were exchanged, compared to its average volume of 186,381. The company's 50 day moving average is $2.05 and its two-hundred day moving average is $1.95. Innate Pharma has a twelve month low of $1.29 and a twelve month high of $3.51.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.